Chemotherapy with doxorubicin in breast cancer patients can cause cardiotoxicity and increase mortality by up to 50%. Vitamin D can cause indirect effects on decreasing heart function. This study examined the relationship of serum blood vitamin D levels with decreased left ventricular systolic function in women with locally advanced breast cancer (LBAC) undergoing doxorubicin chemotherapy. This was an analytical observational study with cross-sectional design. Data collection for vitamin D and echocardiography was performed on patients undergoing chemotherapy for one year. The data were then tested using the contingency coefficient test and regression test. This study found vitamin D deficiency in 17 persons (56.7%). On echocardiography examination, the mean left ventricular ejection fraction (LVEF) was obtained before administering neoadjuvant chemotherapy by 65.0±3, and the average LVEF after administration of neoadjuvant chemotherapy was 61.80±6.283. A total of 18 patients (60%) experienced decreased left ventricular systolic function. There was a significant relationship between vitamin D levels and decreased left ventricular systolic function (p = 0.007). There was a statistically significant relationship between vitamin D levels and decreased systolic function in women with LBAC undergoing neoadjuvant chemotherapy. The higher serum vitamin D level, the lower the decrease in left ventricular systolic function after undergoing Doxorubicin chemotherapy.
- Left ventricle ejection fraction (LVEF)
- Locally advanced breast cancer
- Vitamin D